inflammation and glp 1 Low Dose GLP-1 for Inflammation: Evidence Safety GLP-1 Receptor Agonists as Emerging

JR-K: Methodology, Conceptualization, Funding acquisition, Investigation, Supervision, Formal Analysis, Writing review and editing

ACT 1: Beyond GLP-1 Why Triple Agonists Are Rewriting the Weight Loss Ceiling To understand why newer drugs like Retatrutide are generating so much excitement in obesity medicine, you first need to understand what current medications actually do and where their limitations lie

STAT3 appears to be an important transcription factor recruited during signaling

If the drugs only work while taking them, we can confidently predict that people will take them off and on for long periods of time, or perhaps continuously for years on end

Longterm activation of glucagonlike peptide1 receptor by dulaglutide prevents diabetic heart failure and metabolic remodeling in type 2 diabetes

J Clin Endocrinol Metab 93(9):33733380